|
|
420 Lexington Avenue Suite 450 New York, NY 10170 USA phone:212-584-4180 fax:646-514-7787
|
| Symbol |
NBS |
| Exchange |
AMEX |
| Founded |
2006 |
| Employees |
600 |
|
|
| www.neostem.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| International biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units. |
 |
| Management |
Robin Smith, MD MBA, CEO & Chairman of the Board;
Jian Zhang, General Manager;
Peter Sun, MD General Manager;
Larry May, Chief Financial Officer;
Chris Duignan, CPA, Chief Accounting Officer & VP of Finance;
Catherine Vaczy, ESQ, VP and General Counsel;
Alan Harris, MD PhD FACP FRCP, VP of Drug Development and Regulatory Affairs;
Anthony Salerno, VP of Strategic Development and Academic Affairs |
|
|
|
|
| Keywords |
| peripheral, vascular, congestive, mycardial, cardiac |
|
|
|
|
| Description |
|
NeoStem, Inc. is an international biopharmaceutical company with product and service revenues, global research and development capabilities and operations in three distinct business units: (i) U.S. adult stem cells, (ii) China adult stem cells, (iii) China pharmaceuticals. These business units are expected to provide platforms for the accelerated development and commercialization of innovative technologies and products in both the U.S. and China. |
 |
| Products / Services |
Stem Cell Therapy
Stem Cell Banking
Manufacturing of Generic Pharmaceuticals
|
 |
| Technology / Differentiation |
| Various licensed adult stem cell technologies, including a worldwide exclusive license to VSEL(TM) Technology which uses very small embryonic stem cells. |
 |
| Market / Customers |
Adults in US & China
Over 150 Billion Dollars annual business worldwide
stem cell therapy and pharmaceuticals in China
|
 |
| Status |
| Revenue generating with drugs in pipeline, clinical trials and mature stem cell therapy with early stage stem cell research and development. |
 |
|
|
|
|